Tag:

FTC

Latest Headlines

Latest Headlines

AbbVie scores one against FTC in pay-for-delay AndroGel suit

AbbVie escaped the wrath of the FTC in a pay-for-delay suit over AndroGel generics, as a federal judge who previously threw out antitrust claims against the company rejected the agency's attempts to reconsider its case.  

FTC settles with a pair of UV disinfectant device makers for false claims

The U.S. Federal Trade Commission (FTC) has settled with two makers of ultraviolet light devices that the agency said made false claims about product efficacy. The devices were marketed to consumers with claims that they could eliminate fungus and dangerous bacteria without providing sufficient supporting evidence, the agency said.

Zimmer to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close

Zimmer already has clearances from regulators in Europe and Japan for its proposed $13.4 billion acquisition of Biomet. Now it's close to gaining the go-ahead from the U.S. Federal Trade Commission. Zimmer has disclosed that it has secured buyers for three U.S. businesses to satisfy FTC requests: Zimmer Unicompartmental High-Flex Knee System assets, Biomet Discovery Elbow System assets and Cobalt bone cement assets.

FTC probes Wright, Tornier merger again, may push deal close into the second half

Wright Medical Group had expected to complete its acquisition of Tornier during the first half of this year. But now that is a "best case scenario," according to a statement from the company. The Federal Trade Commission has extended the waiting period until the deal close in order to give Tornier time to deal with the agency's concerns about its lower extremity products.

Ranbaxy-Sun U.S. approval hinges on selling antibacterial drug as FTC notes reach of Indian generic giant

Ranbaxy Laboratories may soon be selling its generic minocycline antibacterial drug to Torrent Pharmaceuticals as a condition for U.S. approval for its merger with Sun Pharmaceuticals.

FTC plows ahead in pay-for-delay suit over AbbVie's AndroGel

The Federal Trade Commission is urging a Pennsylvania federal court to move forward with its pay-for-delay lawsuit against AbbVie, rejecting the company's arguments that it did not keep a generic version of its testosterone powerhouse AndroGel off the market and contending that the suit meets a precedent set last year by the U.S. Supreme Court.

FTC orders Novartis to sell nicotine patch biz to approve consumer deal with GSK

The U.S. Federal Trade Commission found only one antitrust wrinkle in the combo of the consumer health units of GlaxoSmithKline and Novartis and says it has been ironed out. Novartis will sell its Habitrol nicotine patch business so the new joint venture will not have too much market sway in pricing of nicotine patches in the U.S.

Judge tosses RICO claims over AbbVie's Humira, AndroGel copay cards

AbbVie may be under fire from the Federal Trade Commission for delaying AndroGel generics, but it won't have to face racketeering claims over its generics-fighting sales tactics.

FTC takes after AbbVie, Teva for pay-for-delay deal on AndroGel

Even as the FDA is questioning the widespread use of testosterone-boosting drugs for men, the Federal Trade Commission has sued AbbVie and Teva Pharmaceutical Industries for keeping a generic of one out of their reach for years. It is one of the first actions brought by the FTC since the Supreme Court last year said that so-called pay-for-delay deals are not inherently illegal.

The FTC launches new pay-for-delay probes, hoping to win some

In the wake of a Supreme Court ruling that affirmed its anti-pay-to-delay powers, the Federal Trade Commission has launched several new investigations this year, the agency's healthcare chief told Bloomberg. The enforcers are hoping to hit some unlucky pharma company with a $1 billion settlement this year, an FTC official said earlier this year.